Erlotinib
Sign in to save this workspacePrimary targets: EGFR · FDA status: FDA Approved
Selectivity scorecard
KISS
99.75
Gini
0.695
CATDS
0.027
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Erlotinib. Strongest target: EGFR at 99.4% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | EGFR | 99.4% | 0.6% |
| 2 | LOK_STK10 | 89.5% | 10.5% |
| 3 | DDR1 | 83.5% | 16.5% |
| 4 | ERBB4_HER4 | 77.6% | 22.4% |
| 5 | ERBB2_HER2 | 77.5% | 22.5% |
| 6 | MEK5 | 70.9% | 29.1% |
| 7 | ABL1 | 70.5% | 29.5% |
| 8 | SLK_STK2 | 68.6% | 31.4% |
| 9 | ABL2_ARG | 66.8% | 33.2% |
| 10 | FLT3 | 61.3% | 38.7% |
| 11 | LYN | 59.6% | 40.4% |
| 12 | DDR2 | 51.2% | 48.8% |
| 13 | FGFR2 | 50.7% | 49.3% |
| 14 | EPHA6 | 50.0% | 50.0% |
| 15 | LCK | 49.7% | 50.3% |
| 16 | RET | 49.5% | 50.5% |
| 17 | FLT4_VEGFR3 | 48.7% | 51.3% |
| 18 | BLK | 48.0% | 52.0% |
| 19 | MNK1 | 47.6% | 52.4% |
| 20 | RIPK2 | 44.7% | 55.3% |
Selectivity landscape
Where Erlotinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Erlotinib.
Atlas insights for Erlotinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.850 |
| SRR23303752 | — | 0.848 |
| aMVAC.P_005_TURBT_S223 | — | 0.833 |
| SRR10899984 | — | 0.833 |
| SRR12202498 | — | 0.830 |
Annotations
Sign in to read and post annotations.
Loading…